Self-assembling protein nanoparticles (SAPNs) function as repetitive antigen displays and can be used to develop a wide range of vaccines for different infectious diseases. In this article we demonstrate a method to produce a SAPN core containing a six-helix bundle (SHB) assembly that is capable of presenting antigens in a trimeric conformation. We describe the expression of the SHB-SAPN in an E. coli system, as well as the necessary protein purification steps. We included an isopropanol wash step to reduce the residual bacterial lipopolysaccharide. As an indication of the protein identity and purity, the protein reacted with known monoclonal antibodies in Western blot analyses. After refolding, the size of the particles fell in the expected range (20 to 100 nm), which was confirmed by dynamic light scattering, nanoparticle tracking analysis, and transmission electron microscopy. The methodology described here is optimized for the SHB-SAPN, however, with only slight modifications it can be applied to other SAPN constructs. This method is also easily transferable to large scale production for GMP manufacturing for human vaccines.
Introduction
While traditional vaccine development has focused on the inactivated or attenuated pathogens, the focus of modern vaccines has shifted toward subunit vaccines 1 . This approach can lead to a more targeted response, and potentially more efficacious vaccine candidates. However, one of the main drawbacks is that subunit vaccines are not particulates like whole organisms which can result in reduced immunogenicity 2 . A nanoparticle as a repetitive antigen display system can have the benefits of both the targeted subunit vaccine approach as well as the particulate nature of the whole organism 1, 3 .
Among the existing types of nanovaccines, rationally designed protein assemblies allow for the design and development of vaccine candidates that can present multiple copies of the antigen potentially in a native-like conformation 1, 4, 5, 6 . One example of these protein assemblies are the self-assembling protein nanoparticles (SAPNs) 7 . SAPNs are based on coiled-coil domains and are traditionally expressed in Escherichia coli 8 . SAPN vaccine candidates have been developed for a variety of diseases such as malaria, SARS, influenza, toxoplasmosis, and HIV-1 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 . The design of each SAPN candidate is specific to the pathogen of interest, however, the production, purification, and refolding techniques are generally broadly applicable.
One of our current interests is an effective HIV-1 vaccine. In RV144-the only Phase III clinical trial of an HIV-1 vaccine that demonstrated modest efficacy-the reduced risk of infection was correlated with IgG antibodies to the V1V2 loop of the envelope protein 20, 21 . The native-like trimeric presentation of this region is thought to be important for protective immunogenicity 22 . To present the V1V2 loop in as close to nativelike conformation as possible, we developed a proof of principle SAPN vaccine candidate that contained the HIV-1 envelope post-fusion sixhelix bundle (SHB) to present the V1V2 loop into the correct conformation 1. Prepare imidazole-free buffer (8 M Urea, 50 mM sodium phosphate monobasic, 20 mM Tris base, 5 mM TCEP) pH 8.0 (adjusted with 5 N NaOH) and filter it using a 0.22 µm vacuum bottle filtration unit. 2. Resuspend the pelleted cells (from step 1.3) with 40 mL of imidazole-free buffer in one 50 mL conical tube. Sonicate the resuspended cells with a probe on ice for 5 min (4 s of sonication, 6 s of rest) with a sonication output of 150 W. 3. Centrifuge the cellular lysate (40 mL) at 29,000 x g at 4 °C for 25 min in a fixed angle rotor to generate clarified supernatant. Transfer the supernatant to a 150 mL sterile flask and discard the pellet. Dilute the supernatant to 100 mL using the imidazole-free buffer (later in the protocol referred to as "sample"). NOTE: This dilution step is needed to prevent the FPLC system pressure from becoming too high during lysate loading on the column.
Protein purification using a His-column
NOTE: This protocol was performed using an FPLC instrument, but it can be adapted to gravity flow. mL. The column volume and the pressure boxes will be automatically set to the appropriate values. 3. Click on the Method outline button. Drag the following buttons from the Phase library popup menu: equilibration, sample application, column wash, and elution next to the arrow in that exact order. Close the Phase library menu. 4. Click on the equilibration button. The values listed in the table should be "initial buffer B" (4%), "final buffer B" (4%), and "volume (CV)" 5. 5. Click on the Sample application box. In the sample loading box click the radio button for Inject sample on column with sample pump. Make sure the box next to the Use flow rate from method settings is checked in the sample injection with system pump box. Next to the volume box on the right side of the screen change the value to 20 mL. 6. Click on the Column wash button. The values listed in the table should be "initial buffer B" (4%), "final buffer B" (4%), and "volume (CV)" 5. Next to the fraction collection scheme unclick the Enable box. 7. Click on the elution button. The values listed in the table should be "initial buffer B" 0%, "final buffer B" 100%, and "volume (CV)"
5. Next to the fraction collection scheme click on the Enable box. Unclick the Use fraction size from method settings and adjust fraction size to 4 mL in the fill-in box below. 8. Click the save as button on the top of the of the software. Name the file "equilibration". 9. Connect a 5 mL prepacked His-column to the corresponding column port 3 on the FPLC. Both pump A and pump B tubing as well as the sample pump tubing should be placed into 0.22 µm filtered deionized water. Run the equilibration program. 10. Place both pump A and pump B as well as the sample pump tubing into the imidazole-free buffer (Buffer A) and run the equilibration protocol again.
type drop-down menu choose others, Histrap HP, 5 mL. The column volume and the pressure boxes will automatically be set to the appropriate values. 2. Click on the Method outline button. Drag the buttons from the Phase library popup menu: equilibration, sample application, column wash (Wash 1), column wash (Wash 2), column wash (Wash 3), and Elution next to the arrow in that exact order. Close the Phase library menu. 3. Click on the Equilibration button. The values listed in the table should be "initial buffer B" 4%, "final buffer B" 4%, and "volume (CV)" 5. 4. Click on the Sample application box. In the sample loading box click the radio button for Inject sample on column with sample pump. Make sure the box next to the Use flow rate from method settings is checked in the sample injection with system pump box. 5. Next to the volume box on the right side of the screen change the value to 100 mL. Next to the fraction collection scheme click the Enable button. Unclick the Use fraction size from method settings box and then change the fraction size to 4 mL. 6. Click on the first column wash button (Wash 1). The values listed in the table should be "initial buffer B" 4%, "final buffer B" 4%, and "volume (CV)" 10. Next to the fraction collection scheme click the Enable box. Unclick the Use fraction size from method settings and then change the fraction size to 4 mL. 7. Click on the second column wash button (Wash 2). The values listed in the table should be "initial buffer B" 0%, "final buffer B" 0%, and "volume (CV)" 5. Next to the fraction collection scheme click the Enable box. Unclick the Use fraction size from method settings and then change the fraction size to 4 mL. 8. Click on the third column wash button (Wash 3). The values listed in the table should be "initial buffer B" 0%, "final buffer B" 0%, and "volume (CV)" 5. Next to the fraction collection scheme click the Enable. Unclick the Use fraction size from method settings box and then change the fraction size to 4 mL. 9. Click on the Elution button. In the table right click the information listed and, on the menu that comes up, click Delete step. Drag the isocratic gradient button onto the table twice, so that there are two entries. 10. The value for the first entry should read "initial buffer B" 30%, "final buffer B" 30%, and "Volume (CV)" 10. The value for the second entry should read "initial buffer B" 100%, "final buffer B" 100%, and "volume (CV)" 10. Next to the fraction collection scheme click the Enable button. Click the box next to Use fraction size from method settings. 11. Click the Save as button on the top of the of the software. Name the file "purification". Pump A tubing of the FPLC should be placed into the imidazole-free wash buffer while pump B tubing should be placed into the 500 mM imidazole buffer. The sample pump tubing should be placed into the 100 mL sample. 12. Run the "purification" program and wait for the time when the 60% isopropanol is needed (Wash 2). Pause the program, move pump A tubing from the imidazole-free wash into the 60% isopropanol wash. Restart the program. 13. Once the isopropanol step is completed, pause the program again and move pump A tubing back into the imidazole-free wash buffer.
Restart the purification program (the rest of the run is automated).
Purity assessment and protein identification by SDS-PAGE
1. Combine all the fractions corresponding to (i) flow-through (the cell lysate that did not bind to the His column), (ii) Wash 1, (iii) Wash 3 (60% isopropanol wash), and (iv) Wash 3 in separate 50 mL conical tubes. Do not combine the 2 mL fractions from the elution steps. 2. Mix 15 µL from each of the pooled fractions and all fractions from elution steps with 2x Laemmli sample buffer in a 0.5 mL microcentrifuge tube and denature them at 95 °C for 10 min. 3. While the protein denatures, set up the gel running apparatus with 3 stain-free 4-20% precast polyacrylamide gels in 1x Tris-glycine SDS-PAGE running buffer. 4. Load 8 µL of molecular weight marker to the first well and 30 µL of denatured sample to the other wells of the gel. Run the gels at 200 V until the dye front hits the bottom of the gel (about 30 min). Remove the gels from the apparatus and briefly rinse with deionized water. Image the gel immediately using the stain-free imaging system. 5. Identify the fractions that contain protein bands with the correct size (18.07 kDa). Pool all these fractions. from the elution steps with the spectrometer instrument at an absorbance of 280 nm. Generate dilutions that contain 100 ng of protein in 15 µL of imidazole-free buffer for each of these groups. 3. Add 15 µL of 2x Laemmli sample buffer to each 15 µL of the samples and denature them as in step 4.1. Once the denaturing is completed spin down the tubes to ensure all the protein can be transferred. 4. Load samples and the pre-stained marker into a stain-free 4-20% precast polyacrylamide gel. Run the electrophoresis at 200 V until the dye front reaches the bottom of the gel. 5. While the gel runs, make 1 L of TBS-T (20 mM Tris, 150 mM NaCl, and 0.1% Tween 20) and 200 mL of 5% non-fat milk in TBS-T. 6. Use a western blot transfer system to transfer protein onto a nitrocellulose membrane. Use a pre-assembled transfer stack and place the gel on it. Set up the system to run at 25 V for 7 min. Check for the presence of the pre-stained marker on the nitrocellulose membrane indicating a complete transfer. NOTE: All the subsequent steps are performed on an orbital shaker set at 100 rpm at room temperature (RT). 7. Once the transfer is completed, wash blots two times with TBS-T for 10 min each. 8. Block the nitrocellulose membranes (blot) with 5% non-fat milk in TBS-T for at least 1 h. Wash blots two times with TBS-T for 10 min each. 
Protein identification by western blot

Representative Results
The fully assembled SHB-SAPN shown here is built upon protein sequences ( Figure 1A ) that are predicted to fold into a particle that contains 60 copies of the monomer (Figure 1B) . Figure 2 provides an outline of the method for the production, purification, and identification of the SHB-SAPN core. E. coli from a glycerol stock that contained a pPep-T expression vector with gene sequence of the SHB-SAPN core were induced in BL21 (DE3) E. coli. Bacterial cells were successfully grown and lysed under denaturing and reducing conditions.
Total cell lysate was used to purify SHB-SAPN monomers by FPLC using a Ni 2+ column ( Figure 3A) . The FPLC chromatograph demonstrates that protein eluted both at 150 mM and 500 mM imidazole ( Figure 3A) . The chromatogram also shows two other peaks at 185 mL and 210 mL total volume corresponding to the isopropanol wash and the imidazole-free wash, respectively. The fractions and the purity of the recombinant protein were identified by gradient SDS-PAGE gels ( Figure 3B ). The protein of interest was primarily located in fractions 68-79 (278-300 mL total volume). These fractions were combined for further analyses. Western blot with anti-His antibody (N-terminal) and 167-D-IV antibody (Cterminus) indicated that the pooled fractions were indeed the protein of interest (Figure 4A,B) . These blots also demonstrated the presence of the SHB-SAPN multimers. Earlier washes and elution fractions tended to contain a higher concentration of multimerized protein and were therefore excluded.
The samples that contained the protein monomers of interest were folded into the fully assembled SHB-SAPN by dialysis. Particle size distribution was determined by DLS and nanoparticle tracking analysis ( Figure 5A,B) . The DLS identified particles with a Z-average hydrodynamic diameter of 67 nm while the NTA system measured a mean size of 81 nm. The slight size differences were due to the particle sizing techniques, however the size from both analyses were in the expected range of 20-100 nm 8, 24, 25 . SHB-SAPNs were visualized by TEM and the images showed well-formed individual particles with the size distribution obtained from the two particle sizing techniques ( Figure 5C ).
During the purification of the protein, the column was washed with isopropanol to decrease the LPS contamination in the final SHB-SAPN product. To verify if the endotoxin level was acceptable for immunization, the concentration of LPS in SHB-SAPN samples purified with or without the isopropanol wash step was determined by a kinetic LAL assay. The results indicated that the isopropanol wash decreased the endotoxin levels from >0.25 EU/µg to 0.010 EU/µg of SHB-SAPN protein ( Table 1 ). 
Discussion
Nanotechnology provides many advantages and solutions for subunit vaccine development. Nanovaccines can repeatedly present antigens as particulates to the host immune system increasing immunogenicity
